Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Polman

Showing results (181-190 of 290) with videos related to

Pageof 29
Sort By:
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|May 9, 2000
Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disabilityG J Lycklama à Nijeholt, J A Castelijns, R H Lazeron, et al.
Journal of Neurology|April 29, 1998
Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI studyF J Barkhof, M Elton, J Lindeboom, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 19, 2008
Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?T Korteweg, M Rovaris, V Neacsu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 15, 2012
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progressionC E Teunissen, M Sombekke, L van Winsen, et al.
Neurology|February 9, 2011
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MSA Vennegoor, M P Wattjes, E T L van Munster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 13, 2011
Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scalesJ M Sonder, L V A E Bosma, F A H van der Linden, et al.
Annals of Neurology|September 8, 2000
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?A H van Boxel-Dezaire, S C van Trigt-Hoff, J Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practiceL F van der Voort, A Kok, A Visser, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1997
Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trialsL Truyen, F Barkhof, M Tas, et al.
Annals of Neurology|September 8, 2000
Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients?S A Morré, C J De Groot, J Killestein, et al.
Pageof 29

Showing results (181-190 of 290) with videos related to

Sort By:
Pageof 29
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|May 9, 2000
Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disabilityG J Lycklama à Nijeholt, J A Castelijns, R H Lazeron, et al.
Journal of Neurology|April 29, 1998
Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI studyF J Barkhof, M Elton, J Lindeboom, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 19, 2008
Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?T Korteweg, M Rovaris, V Neacsu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 15, 2012
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progressionC E Teunissen, M Sombekke, L van Winsen, et al.
Neurology|February 9, 2011
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MSA Vennegoor, M P Wattjes, E T L van Munster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 13, 2011
Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scalesJ M Sonder, L V A E Bosma, F A H van der Linden, et al.
Annals of Neurology|September 8, 2000
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?A H van Boxel-Dezaire, S C van Trigt-Hoff, J Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practiceL F van der Voort, A Kok, A Visser, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1997
Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trialsL Truyen, F Barkhof, M Tas, et al.
Annals of Neurology|September 8, 2000
Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients?S A Morré, C J De Groot, J Killestein, et al.
Pageof 29